The Top 5 Biosimilar Articles for the Week of March 8
Here are the top 5 biosimilar articles for the week of March 8, 2021.
Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilar articles for the week of March 8, 2021.
Number 5: Alteogen, a Republic of Korea-based biopharmaceutical developer, said it has successfully completed a phase 1 clinical trial of an aflibercept biosimilar referencing Eylea.
Number 4: Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of Biosimilars at Cardinal Health, discusses motivating factors that affect use of biosimilars in oncology.
Number 3: Survey results show that oncologists are embracing biosimilars not just in supportive care but for therapeutic uses also.
Number 2: A study of comparative clinical efficacy trials for biosimilars suggests that these trials are often larger and as rigorous as those done for originator products, and often are more costly than for new molecular entities.
Number 1: Minnesota legislators introduce what could possibly become the first law to curtail payers' rights to determine which biologics patients have access to.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Phase 1 Study Finds Comparable PK, PD Parameters in Biosimilar GP40141 vs Reference Romiplostim
November 25th 2023A phase 1 analysis confirms that romiplostim biosimilar candidate GP40141 has comparable pharmacokinetic (PK) and pharmacodynamic (PD) parameters in healthy volunteers compared with the reference product.
